VRDN — Viridian Therapeutics Balance Sheet
0.000.00%
- $1.10bn
- $464.23m
- $0.30m
Annual balance sheet for Viridian Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 128 | 197 | 425 | 477 | 718 |
Net Total Accounts Receivable | |||||
Net Total Receivables | — | 0.451 | 0.102 | 0.102 | 0 |
Prepaid Expenses | |||||
Total Current Assets | 130 | 200 | 431 | 486 | 738 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.787 | 2.06 | 2.94 | 3.34 | 3.44 |
Other Long Term Assets | |||||
Total Assets | 131 | 204 | 435 | 490 | 742 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 10.7 | 13.6 | 33.3 | 26.6 | 47.9 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 11.2 | 16 | 40 | 48.4 | 70.8 |
Redeemable Preferred Stock | |||||
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 120 | 188 | 395 | 442 | 672 |
Total Liabilities & Shareholders' Equity | 131 | 204 | 435 | 490 | 742 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |